ADmit Therapeutics SL

[Not Yet Scheduled]
We are developing a diagnostic platform for an early Alzheimer's diagnosis analyzing a pool of epigenetic biomarkers in blood samples.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Spain
Year Founded:
2017
Main Therapeutic Focus:
Lead Product in Development:
MAP-AD platform
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
ADmit Therapeutics S.L.